Idaho is currently home to 371 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/06/2024
Locations: Site 119, Boise, Idaho
Conditions: Major Depressive Disorder
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
NCT04076813
Recruiting
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Kootenai Hospital District dba Kootenai Health, Coeur d'Alene, Idaho
Conditions: Myocardial Infarction
Register for Updates
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
NCT05408845
Recruiting
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab e... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Register for Updates
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530
Recruiting
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Beacon Cancer Care, Coeur d'Alene, Idaho
Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
Register for Updates
INTIBIA Pivotal Study
NCT05250908
Recruiting
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Gender:
All
Ages:
Between 22 years and 80 years
Trial Updated:
02/05/2024
Locations: Rosemark WomenCare Specialists, Idaho Falls, Idaho
Conditions: Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Register for Updates
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT05050084
Recruiting
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Prostate Adenocarcinoma
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to <13 years of age.
Gender:
All
Ages:
Between 3 years and 13 years
Trial Updated:
02/05/2024
Locations: St Luke's Hospital, Boise, Idaho
Conditions: Amblyopia
Register for Updates
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
NCT05785832
Recruiting
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Type 2 Diabetes Treated With Insulin
Register for Updates
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523
Recruiting
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
02/01/2024
Locations: Boise Kidney & Hypertension Institute, Meridian, Idaho
Conditions: Diabetic Kidney Disease, Chronic Kidney Diseases
Register for Updates
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Coeur d'Alene, Idaho
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
NCT05587309
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/30/2024
Locations: Research Site 151, Boise, Idaho
Conditions: Erosive Esophagitis
Register for Updates